Skip to main content
SpringerLink
Log in

Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy

  • Invited Commentary
  • Published:
Current Urology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mittan D, Miller E, Basler J, et al.: Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002, 87:3656–3661.

    Article  PubMed  CAS  Google Scholar 

  2. Smith MR, McGovern FJ, Zeitman AL, et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948–955.

    Article  PubMed  CAS  Google Scholar 

  3. Smith MR, Eastham J, Gleason DM, et al.: Randomized, controlled trial of zolendronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008–2012.

    Article  PubMed  CAS  Google Scholar 

  4. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154–164.

    Article  PubMed  CAS  Google Scholar 

  5. The WHO Study Group: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Geneva: World Health Organization; 1994.

    Google Scholar 

  6. Faulkner KG, Stetten E, Miller P: Discordance in patient classification using T-scores for the diagnosis of osteoporosis in men. J Clin Densitom 1999, 2:343–350.

    Article  PubMed  CAS  Google Scholar 

  7. Welch MD, Bruder JM: Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. J Bone Miner Res 2002, 17:S411.

    Google Scholar 

  8. Faulkner KG, Orwoll E: Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom 2002, 5:87–93.

    Article  PubMed  Google Scholar 

  9. Orwoll E, Ettinger M, Stuart W, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604–610.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Endocrinology, University of Texas Health Science Center, 7703 Floyd Curl Drive, 78229, San Antonio, TX, USA

    Jan M. Bruder MD

Authors
  1. Jan M. Bruder MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bruder, J.M. Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy. Curr Urol Rep 6, 157–158 (2005). https://doi.org/10.1007/s11934-005-0001-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-005-0001-x

Keywords

Search

Navigation